Mon Jul 28, 2014 5:49pm EDT0 Comments Tweet Share this EmailPrint Related Topics Health »
(Reuters) - Targacept Inc said it was stopping the development of its bladder drug after it failed to show a statistically significant reduction in episodes of urinary incontinence in a mid-stage study.
The company's shares fell about 32 percent in extended trading.
The company also said based on results from this and previous trials, modulation of nicotinic receptors did not "appear to predict new treatments with a meaningful improvement over the current standard of care."
Targacept stopped the development of its Alzheimer's drug earlier this month and its schizophrenia drug last year.
(Reporting By Amrutha Penumudi; Editing by Don Sebastian)FILED UNDER: Health Tweet this Link this Share this Digg this EmailPrintReprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/Comments (0)Be the first to comment on reuters.com. Add yours using the box above.
View the Original article